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license (http://creativeDementia Risk Score is a validated tool to predict late-life dementia risk (20 years later), based on
midlife vascular risk factors. The goal was to render this prediction tool widely accessible.
Methods: The CAIDE Risk Score (mobile application) App was developed based on the CAIDE
Dementia Risk Score, involving information on age, educational level, hypertension, hypercholester-
olemia, obesity, and physical inactivity.
Results: The CAIDE Risk Score App is an evidence-based practical tool, which allows users to
detect their individual risk, provides guidance for risk modification, and suggests consulting a health
care practitioner if needed. Moreover, it allows practitioners to discuss preventive measures and
monitor risk reduction.
Conclusions: The CAIDE Risk Score App is the first to predict the risk for dementia through an
important evidence-based tool. The App can encourage users to actively decrease their modifiable
risk factors and postpone cognitive impairment and dementia.
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commons.org/licenses/by-nc-nd/4.0/).to double every 20 years, reaching 76 million in 2030 and
136 million in 2050 [1,2]. The estimated annual
worldwide socioeconomic cost of dementia was US $604
billion in 2010, creating a daunting burden [3]. Considering
that there are no available curative treatments for dementia,
prevention has recently been highlighted as a major public
health priority by the G8 dementia summit and the World
Health Organization (WHO) [4,5].
During the last decade, findings from observational
studies have revealed several important midlife vascular
and metabolic risk factors that increase the risk forimer’s Association. This is an open access article under the CC BY-NC-ND
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tors, the CAIDE (Cardiovascular Risk Factors, Aging,
and Incidence of Dementia) Dementia Risk Score was
developed to identify individuals at increased risk for de-
mentia, who necessitate preventive interventions to reduce
their risk [7]. This risk score is based on multifactorial
risk estimation using age, hypertension, hypercholester-
olemia, physical inactivity, obesity, and educational level
as the model parameters. The CAIDE Dementia Risk
Score was also externally validated in a multiethnic pop-
ulation in the United States [8]. Of interest, the addition of
other midlife risk factors to the CAIDE risk score (central
obesity, depressed mood, diabetes mellitus, head trauma,
poor lung function, and smoking) did not improve its pre-
dictability [8]. Although taking into account the preva-
lence and co-occurrence of modifiable risk factors, it
was estimated that approximately one third of AD cases
are attributable to seven risk factors (midlife hyperten-
sion, diabetes mellitus, physical inactivity, midlife
obesity, depression, smoking, and low education) [9]. A
reduction of 10%–20% in these risk factors may reduce
AD prevalence by 8%–15% by 2050, which highlights
the potential for preventive strategies [9].
Using the original CAIDE Dementia Risk Score, the
Finnish Geriatric Intervention Study to Prevent Cognitive
Impairment and Disability (FINGER) recruited partici-
pants who at baseline had a CAIDE Dementia Risk Score
of 6 points (indicating the presence of modifiable risk
factors) and cognitive performance at the mean level or
slightly lower than expected for age. The multimodal
intervention consisted of nutritional guidance, exercise,
cognitive training, and intensive monitoring of vascular
and metabolic risk factors. This study demonstrated that
when at-risk participants were subjected to an intensive
multimodal lifestyle intervention for 2 years, there was
a significant beneficial intervention effect on global cogni-
tion score; the score in the intervention group was 25%
higher than that in the control group [10]. This is the first
demonstration that cognitive functions can be maintained
or improved among older adults. Moreover, the risk of
cognitive impairment was 31% higher in the control group
compared with the intervention group. These findings
indicate that the CAIDE Dementia Risk Score is an
extremely valuable tool for detecting individuals at high
risk for dementia, who are also likely to benefit from life-
style interventions and proper management of vascular
risk factors, given that most of their risk factors for de-
mentia and cognitive decline are modifiable.
Considering the utility of this risk score, the investiga-
tors who have developed the CAIDE Dementia Risk
Score [7] have sought to make it more accessible to
health care practitioners and the general public through
the use of mobile health (mHealth) technologies and
more precisely through developing a mobile application
(App). mHealth Apps can serve various functions such
as providing evidence-based information, alert systems,remote consultation/monitoring and diagnostic/treatment
support, assessing compliance to medication regiments,
and promoting healthy lifestyles (e.g., nutrition, physical
activity, sleep) [11,12]. Some Apps also collect
information for databases that can be used for research
analyses and improvement of health care systems [13].
As recently highlighted, the most marked potential for
mHealth is the prevention of chronic noncommunicable
diseases (NCDs), which can significantly alleviate the
burden on individuals and health care systems through
cost reductions [12]. The WHO and the International
Telecommunication Union have recently launched the
collaborative mHealth initiative to prevent and treat
worldwide and enforce appropriate legislations [14]. Us-
ing Apps can encourage individuals to take responsibility
for their health and lead healthy lifestyles that prevent
various NCDs [13,15]. Consistent with this rationale,
the CAIDE Dementia Risk Score App can play a
significant role in decreasing dementia incidence and
related costs, while enhancing individuals’ control over
their lifestyle-related risk factors.
Numerous Apps have been developed for diabetes,
depression, cardiovascular diseases, and lifestyle changes
[16,17]. To illustrate, Apps in the health and fitness
category range between .11,000 (Google play for
Android) and 20,000 (App Store for Apple iOS),
whereas Apps for the medical category range between
5000 (Google play) and 14,000 (App Store) [17]. Although
many Apps and mHealth technologies have been created to
enable older adults to live independently and “age-in-
place,” to the best of our knowledge, none have been
developed to estimate dementia risk earlier in life.
The goals of the CAIDE Dementia Risk App are to (1)
assess the 20-year risk of developing dementia with the
CAIDE Dementia Risk Score among users, (2) inform
users about the meaning of their risk score through a
graphic display of their risk level, (3) provide users with
guidance and suggestions for methods to decrease their
risk score (e.g., specific recommendations for increasing
physical activity), and (4) recommend users to consult
with a health care practitioner (if needed) to discuss
appropriate lifestyle interventions and management of
vascular and metabolic risk factors.2. Methods
2.1. Summary of methods for the CAIDE Dementia Risk
Score
The CAIDE Risk Score App has been developed based
on the CAIDE Dementia Risk Score, which includes com-
mon and easily available measures. For a more detailed
description of the risk score, including analyses and
results, see [7]. The CAIDE study recruited participants
from four independent population-based random samples
that were involved in the North Karelia Project
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minants in Cardiovascular disease (MONICA) Project
(FINMONICA) study [18]. Local ethics committees had
approved the study, and all participants gave written
informed consent. At the baseline (midlife) and reexami-
nation (late life) assessments, survey methods were
compiled and carried out according to international stan-
dards and recommendations based on the WHO MONICA
project [19]. The surveys consisted of a self-administered
questionnaire on medical history, current health behavior,
and health status. Data on dementia diagnosis and cogni-
tive status assessments were also based on international
standards and recommendations using a three-stage proto-
col: (1) screening phase: participants who scored 24 on
the Mini-Mental State Examination were referred for
further examinations. (2) clinical phase included neuro-
logic and cardiovascular examinations and detailed neuro-
psychological testing. (3) differential diagnostic phase
involving blood tests, neuroimaging (magnetic resonance
imaging and computed tomography), cerebrospinal fluid
analyses, and an electrocardiogram. According to the
diagnostic criteria of the Diagnostic and Statistical
Manual of Mental Disorders (4th edition) [20], dementia
and Alzheimer’s disease were diagnosed according to
the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and
Related Disorders Association [21].
To simplify the scoring methods, variables included in
the risk score were dichotomized using standard cutoffs
(sex, body mass index, systolic blood pressure, diastolic
blood pressure, total cholesterol, current smoking status,
and physical activity level) or categorized in tertiles
(age and education).
A supplementary risk score was developed including the
apolipoprotein ε (APOE) genotype status in the model
(APOE ε4 carriers vs. noncarriers). However, considering
that inclusion of APOE ε4 was not found to change the pre-Fig. 1. Receiver-operating characteristic curves showing the performance
of the dementia risk scores in predicting the risk of dementia in 20 years
among those in middle age. The AUC for model 1 was 0.769 (95% CI:
0.709–0.829). The AUC for model 2 was 0.776 (95% CI: 0.717–0.836).
(Figure adapted from [7].) Abbreviation: CI, confidence interval.dictive value of the model, the App did not include APOE ε4.
In summary, the receiver-operating characteristic curves
demonstrate that the dementia risk score effectively pre-
dicted subsequent dementia. For the basic risk score (model
1), the area under the curve was 0.77 (95% confidence inter-
val: 0.71–0.83; Fig. 1).2.2. Methods for the development of the CAIDE Risk Score
App
To develop the CAIDE Risk Score App, we established
a collaboration with Merz Pharmaceuticals GmbH (Ger-
many), which engages in research and development of
innovative pharmaceutical and medical products for
various medical fields, including neurology and derma-
tology.
2.2.1. Technical description of the CAIDE Risk Score App
Two versions of the App are available, one for health
care personnel and one for the general public, and this se-
lection only needs to be made the first time the App is
used. The main difference between the two versions is
that a health care provider can enter a profile including
his/her name, name and contact details of practice, and
Web site.
The App can be downloaded for free from the App
Store and may be used on an iPhone or iPad. The App
is currently available in five languages: English (as
default), German, French, Spanish, and Russian. Addi-
tional languages including Swedish and Finnish will be
added in the near future. Within a few months of launch-
ing the App, .700 users have downloaded it, and this
number is continuing to increase across the following re-
gions: Europe, United States and Canada, Asia Pacific,
Latin America and Caribbean, Africa, Middle East, and
India.Fig. 2. CAIDE Risk Score App screenshot displaying the demographic in-
formation required for calculation of the risk score. Abbreviations: CAIDE,
Cardiovascular Risk Factors, Aging, and Incidence of Dementia; BP, blood
pressure.
Fig. 4. Explanation of the increased risk score. Abbreviation: BP, blood
pressure.
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The CAIDE Risk Score App was developed based on the
CAIDE Dementia Risk Score described previously, which
allows the prediction of the later risk of dementia using
the risk profile in midlife (age 40–65 years).
Users—whether lay people who want to calculate their
own risk or health care providers who are calculating the
risk of their clients—are asked to enter age, sex, date of
birth, height and weight, serum cholesterol, systolic and
diastolic blood pressure, physical activity status, and
years of education (as shown in Fig. 2). The App then
calculates the risk score and displays the risk level. For
scores in the “normal” range (score of 8–9), an orange
bar appears; if the risk is lower than the normal range
(score of 0–7), a green bar appears; and if it is higher
than average (score of 10–15), a red bar appears (as
shown in Fig. 3). In the background information for sys-
tolic blood pressure and cholesterol, users are advised to
discuss preventive lifestyle interventions with their
physician if necessary.
Even if the risk scores are clustered in intervals leading
to the same probability of developing dementia, the App
visualizes small changes of 1 point in risk score within
the same cluster by filling the bar more or less with color.
This is for motivational reasons so that even a single point
of reduction may be seen. Also the green and red colors
are differentiated: the lower the risk score the darker the
green color and the higher the risk score the darker the
red color becomes.
2.2.3. Guidance for risk reduction
The CAIDE Risk Score App provides an explanation of
the risk score and provides a probability percentage,
comparing it to the average probability of developing de-
mentia (Fig. 4). The App also includes simple information
on how the risk factors can be modified. For example, howFig. 3. CAIDERisk Score App screenshot showing a graphic representation
of the risk score. Abbreviations: CAIDE, Cardiovascular Risk Factors, Ag-
ing, and Incidence of Dementia; BP, blood pressure.a short duration of formal education can be compensated
by various cognitively stimulating activities and how one
can easily increase physical activity in daily life. To
reduce systolic blood pressure, it is suggested to exercise;
reduce weight, salt intake and levels of psychological
stress; and avoid excess alcohol consumption. As back-
ground information about serum cholesterol, three bullets
points provide examples of food sources rich in unsatu-
rated fatty acids, examples of which sources of animal
fat to reduce or increase and encourages the increase of
fibers. The App also recommends referring to a physician
for more guidance and appropriate treatments if needed
(e.g., to decrease high cholesterol levels or blood pressure
levels).
2.2.4. Data protection and compliance
Any personal information or patient data saved in the
CAIDE Risk Score App will only be stored locally on the
user’s device and cannot be accessed by Merz Pharmaceuti-
cals GmbH or anybody else. If the App contains personal in-
dentification data, the device should be handled with the
same care as any hard copy of a medical record as explained
in the Data Protection Disclaimer.
Because the App merely predicts risk and does not make
diagnoses or suggest treatments or changes of current
medication dosages, it is not classified as a medical device
and, therefore, needs no regulatory approval by health
authorities [22].3. Discussion
The CAIDE Risk Score App is the first evidence-based
App to estimate future dementia risk in midlife. It is a prac-
tical and user friendly App that complies with security and
privacy guidelines and is free of charge to all users. The
App is intended for use by health practitioners and the gen-
eral public. It allows users to detect their risk, obtain
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gestions on how to modify their risk factors. The App also
advises users to consult a health care practitioner if needed.
Moreover, it allows practitioners to discuss preventive mea-
sures and thereafter monitor whether the individual’s de-
mentia risk has decreased based on provided guidance and
interventions.
After the use of the CAIDE Dementia Risk App, it is
important for users with high risk scores to seek further
appropriate interventions, which could include other
mHealth tools or validated Apps of high quality that focus
on reducing the risk factors involved in the CAIDE risk
score. Users would benefit from mHealth tools/Apps
developed for increasing physical activity levels,
improving nutrition, and managing weight. In fact, usage
of such Apps to improve lifestyle is already highly popu-
lar and has the potential to significantly reduce the rates of
chronic disease and health care costs [13]. The CAIDE
Risk Score App is an important tool to identify people
who might benefit most from using such Apps and who
may not be inclined to use them without knowing about
their increased risk for dementia. Similar to more recent
“multimodal” dementia prevention trials, the most effec-
tive Apps are likely to be those that simultaneously target
several dementia risk factors (nutrition, physical activity,
weight, and vascular risk factors). Moreover, “multimodal
Apps” may decrease the burden of having to use and keep
track of several Apps, facilitating usage for lay people and
health care providers who are monitoring the progress of
dementia risk reduction.
The effectiveness of some Apps may be subjected to un-
dergoing randomized controlled trials (RCTs), especially for
those with little or no evidence behind them. However,
regarding the CAIDE Risk Score App, physicians and other
health professionals do not need to wait for RCT evidence
before they can start recommending the App, considering
that (1) the CAIDE risk score is evidence-based and has
been validated both internally and externally, (2) prevalence
of dementia has been and continues to increase at an alarm-
ing rate, considering the aging of the population worldwide,
(3) scientific evidence strongly indicates that lifestyle-
related changes can decrease the risk of cognitive impair-
ment as well as that of other chronic conditions such as
type 2 diabetes, cancer, and cardiovascular disease, and (4)
there are no risks attached to using the CAIDE Dementia
Risk App. So, although there is no RCT evidence for the
CAIDE App itself, the evidence for the risk score and pre-
ventive lifestyle interventions is compelling, as demon-
strated by the FINGER study [10]. As suggested by the
Institute for Healthcare Informatics report, although evi-
dence for the effectiveness of Apps is needed, there is no
need for a 3- to 4-year RCT that is similar to the process
of drug development [13].
Considering the wide range of available Apps, people
are increasingly finding it difficult to make informed
choices regarding Apps that can be effective and reliable,whereas they tend to rely on other customers’ reviews
[13]. Similarly, physicians and other health professionals
are cautious in recommending Apps if they have little or
no information regarding the quality, validation, and
effectiveness of a particular App. Physicians also perceive
the need to first ensure that legal, privacy, and security
requirements/regulations are all met. In contrast to many
other Apps, privacy and security are not sources of
concern for the CAIDE Risk Score App. Physicians are
also weary of prescribing Apps for which people have
to pay, as reimbursement may be an issue for various rea-
sons. Not only is the CAIDE Risk Score App based on
well-validated scientific evidence, it is free of charge to
all users, which will prevent caution in recommending it
to the general population, where many would benefit
from using it.
A review of mHealth Apps targeting prevalent conditions
suggested that the primary motivation for developing Apps
is for economic and commercial motives rather than research
[16]. Moreover, Apps developed for diabetes illustrate a lack
of personalized health education, which is essential and rec-
ommended by evidence-based clinical guidelines [23].
There is also a lack of prevention Apps that are based on vali-
dated models and theories of behavior change [24]. To
bridge such gaps, it will be crucial to establish collaborative
initiatives between industries developing Apps and aca-
demic research institutes [24]. It will also be important to
create and use platforms that allow for data pooling and
shared analyses across Apps [25].
Usage of the CAIDE Risk Score App by a wide audience
has a promising potential to detect people’s individual risk for
cognitive decline andmotivate them to pay attention to appro-
priate lifestyle changes. This may decrease the burden on
medical and health services through decreasing or postponing
the onset of dementia and other NCDs such as diabetes, car-
diovascular diseases, and cancer, which share the same risk
factors included in the CAIDE Dementia Risk Score.Acknowledgments
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1. Systematic review: Dementia and Alzheimer’s dis-
ease have reached epidemic proportions, with heavy
economical, social, and medical burdens. Early
detection and prevention are highlighted as impor-
tant public health priorities, and there is a need for
widely accessible tools to predict dementia risk.
2. Interpretation: The CAIDE (Cardiovascular Risk
Factors, Aging, and Incidence of Dementia) Demen-
tia Risk score is a validated tool to predict late-life
dementia risk, based on the presence of midlife
vascular risk factors (e.g., hypertension, low educa-
tion, obesity, and physical inactivity). To make this
prediction tool more widely available, a mobile
application (App), “The CAIDE Risk Score App”
has been developed and is free of charge. It is the first
evidence-based App intended for use by patients and
health practitioners.
3. Future directions: The use of the App will encourage
users to actively decrease their risk factors and has
the potential to postpone the onset of dementia, as
well as other chronic conditions.
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